CTIS2023-510297-14-00进行中（未招募）1 期
Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID): a single-center, randomized, double-blind and placebo-controlled phase 2 clinical basket trial - EXC2167-5
niversitaetsklinikum Schleswig-Holstein AöR0 个研究点目标入组 112 人开始时间: 2024年1月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 112
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Participants with pemphigus vulgaris / foliaceus (PV/PF) and having mild to moderate disease activity as defined by a PDAI = 6 and = 45., Participants with mucous membrane pemphigoid (MMP) and having mild to moderate disease activity as defined by a MMPDAI of = 6 and = 45., Participants with polymyositis (PM) or dermatomyositis (DM) and having elevated plasma concentrations of the creatine kinase (CK) of = 300 U/L and = 3000 U/L. Concomitant diagnoses of other rheumatic diseases (overlaps) are allowed., Participants with primary sclerosing cholangitis (PSC) and having elevated plasma concentrations of the alkaline phosphatase (AP) of = 1.5 times above the upper limit of normal. Concomitant diagnosis of inflammatory bowel diseases is allowed., Age of participants: = 18 years and = 80 years.
排除标准
- •Severe impairment of vital organ or life-threatening disease, Chronically active infectious diseases
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patientsEUCTR2015-005347-14-GBCHU DE NIMES216
Unknown
1 期
Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）Macrophage Activation SyndromeNCT02569463Peking University People's Hospital6
已完成
1 期
Ultra Low Dose Interleukin-2 in Healthy VolunteersHematologic DiseasesNCT01445561National Heart, Lung, and Blood Institute (NHLBI)22
已完成
不适用
Efficacy of subcutaneous interleukin-2 (IL-2) in the treament of advanced HIV-1 infections in persons with CD4+ T lymphoytes <100/mm3 and undetectable plasma viral loadInfections and Infestations: Human immunodeficiency virus (HIV)Infections and InfestationsHuman immunodeficiency virus (HIV)ISRCTN34382898Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)30
进行中（未招募）
1 期
A Phase I-IIa trial on low-dose IL-2 (Aldesleukin) treatment for immunological dysregulation in common variable immunodeficiency (CVID)autoimmune enteropathy (AIE) in common variable immunodeficiency (CVID).MedDRA version: 19.0Level: PTClassification code 10021449Term: Immunodeficiency common variableSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 19.0Level: LLTClassification code 10017922Term: Gastroenteropathy NOSSystem Organ Class: 100000004856EUCTR2015-003369-27-DEniversitätsklinikum Freiburg6